Welcome to the lab of Paul A. Northcott, PhD
The Northcott Lab aims to fully characterize the molecular, cellular, and biological basis of medulloblastoma, one of the most prevalent types of malignant childhood brain cancer. The foundation of our work is based upon recent comprehensive next-generation genomic analyses through which we have discovered the genes, pathways, and molecular processes recurrently altered in patients with medulloblastoma. Our current focus is to summarize these somatic alterations in the context of medulloblastoma subgroups and functionally validate candidate driver genes and pathways using a variety of technically advanced in vivo methodologies. In addition, we are working closely with the Division of Neuro-Oncology at St. Jude to improve understanding of how specific genomic variants correlate with the demographic and clinical features of medulloblastoma patients treated on clinical trials conducted at St. Jude Children’s Research Hospital. Collectively, these studies will lead to a better understanding of the molecular and cellular origins of medulloblastoma and translate to improved stratification and treatment options for patients and their families.
St. Jude scientist named Pew-Stewart Scholar: Paul Northcott selected for support as a promising early-career scientist focused on cancer research.
St. Jude Children’s Research Hospital News Release. June 9, 2016.
Read the latest research article with Paul Northcott as co-leader of the study
Active medulloblatoma enhancers reveal subgroup-specific cellular origins
Nature January 27, 2016. Epub ahead of print. doi: 10.1038/nature16546.